These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 12494221)

  • 1. [Simvastatin in management of patients with primary hypercholesterolemia: tolerability and efficacy of daily doses 10-80 mg].
    Susekov AV; Solov'eva EIu; Rozhkova TA; Kotova LA; Akhmedova ZA; Kukharchuk VV
    Kardiologiia; 2002; 42(1):33-6. PubMed ID: 12494221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
    Davidson MH; Stein EA; Hunninghake DB; Ose L; Dujovne CA; Insull W; Bertolami M; Weiss SR; Kastelein JJ; Scott RS; Campodónico S; Escobar ID; Schrott HG; Bays H; Stepanavage ME; Wu M; Tate AC; Melino MR; Kush D; Mercuri M; Mitchel YB;
    Nutr Metab Cardiovasc Dis; 2000 Oct; 10(5):253-62. PubMed ID: 11213534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Simvastatin (40 mg/day) in patients with hereditary hypercholesterolemia: effect on high density lipoprotein cholesterol].
    Susekov AV; Solov'eva EIu; Zubareva MIu; Kukharchuk VV
    Kardiologiia; 2002; 42(12):38-41. PubMed ID: 12494016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
    Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D
    Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study.
    Pedersen TR; Jahnsen KE; Vatn S; Semb AG; Kontny F; Zalmai A; Nerdrum T
    Clin Ther; 2000 Aug; 22(8):949-60. PubMed ID: 10972631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
    Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia.
    Copher HR; Stewart RD
    Pharmacotherapy; 2002 Sep; 22(9):1110-6. PubMed ID: 12222546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.
    Kim SH; Kim MK; Seo HS; Hyun MS; Han KR; Cho SW; Kim YK; Hoon Park S
    Clin Ther; 2013 Sep; 35(9):1350-60.e1. PubMed ID: 23998970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
    Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
    Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
    Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.